ANTI-IDIOTYPIC ANTIBODY INDUCTION OF ANTITUMOR RESPONSE

Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions thereof to primary antibodies which bind...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DURRANT, LINDA, GILLIAN, BALDWIN, ROBERT, WILLIAM, AUSTIN, ERIC, BERTRAM, BYERS, VERA, S
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions thereof to primary antibodies which bind selectively to an antigenic determinant of gp72 are provided to mediate the humoral and cellular components of the patient's immune system. The immunogenic agents find use both in vivo and in vitro. L'invention concerne de nouvelles compositions et méthodes de stimulation du système immunitaire d'un patient contre des cellules tumorales qui portent un antigène gp72 associé à la tumeur et révèlent un effet tumeuricide. Des anticorps monclonaux anti-idiotypiques humains et leurs régions idyotopiques sur des anticorps primaires qui se lient sélectivement à un déterminant antigénique de gp72 servent de médiateurs aux composants humoraux et cellulaires du système immunitaire du patient. Les agents immunogéniques s'utilisent tant in vivo qu'in vitro.